Toremifene

CLINICAL USE

Hormone dependent metastatic breast cancer in post-menopausal women

DOSE IN NORMAL RENAL FUNCTION

60 mg daily

PHARMACOKINETICS

Molecular weight : 406

%Protein binding : >99.5

%Excreted unchanged in urine : 10% as metabolites

Volume of distribution (L/kg) : 580 litres

half-life – normal/ESRD (hrs) : 5 days/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Unlikely to be dialysed.

HD : Unlikely to be dialysed.

HDF/high flux : Unknown dialysability.

CAV/VVHD : Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anticoagulants: enhanced anticoagulant effect of coumarins

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

As it is not renally excreted, it may be possible to prescribe the normal dose in dialysis patients, although it has not previously been used in this population .

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home